

Best Upfront Treatment Strategy for Multiple Myeloma: Cure vs. Control?




Lalit Kumar

Department of Medical Oncology

IRCH, All India Institute of Medical Sciences, New Delhi 110029

MM: Goals of Treatment !



Multiple Myeloma : Treatment Summary

Induction therapy


```
graph TD; A[Induction therapy] --> B[Consolidation (ASCT)]; B --> C[Maintenance therapy];
```

Consolidation (ASCT)

Maintenance therapy

Treatment Algorithm

Age ≤ 65 Yrs
Candidates for transplant
Induction therapy 4-6 cycles



Induction Therapy

Regimen	# Pts	≥PR (%)	≥VGPR (%)	PFS	OS
Thal/dex	235	63	43.8	14.9 mon	68% @2 Y
Len/dex	34	91	38	74% @ 2 Y	91% @2 Y
Bort-dex	52	66	31	ng	ng
PAD	65	97.1	50	83% @ 2Y	92% @ 2Y

Palumbo & Rajkumar, Leukemia 2009, JCO 2008, Blood 2005, Blood 2008, Hemtologica, 2006, Blood 2007

Induction regimen prior to ASCT : Phase III studies

Study	n	Regimen	Response				OS (%)
			Post induction (%)		Post ASCT (%)		
			nCR	VGPR	nCR	VGPR	
IFM (2010)	240	Vel-D	14.8	37.7	35	54.3	<u>81.4@3 Y</u> 77.4@3Y
	242	VAD	8	15.1	18.4	37.2	
Cavo (2010)	236	VTD	31.1	62	55	82	86@3Y 84@3Y
	238	TD	1.0	28	41	64	
Lokhorst (2008)	201	TAD	3	33	16	49	NR NR
	201	VAD	2	15	11	32	
Rajkumar (2010)	214	RD	18	50	NR	NR	75@2Y 87@2Y
	208	Rd	14	40	NR	NR	

JCO,2010; Lancet,2010;Hematologica,2008;Lancet Onclogy,2010

Induction regimen prior to ASCT : Phase III studies

study	n	Regimen	Response		PFS
			Post induction (%)	Post ASCT (%)	
			CR	CR	
Pathema Group (2012)	130	VTD	35	46	56.2 mon
	127	TD	14, P<001,	24	28.2 mon,
	129	VBMCP/ VBAD/B	21,p<.01	38	p<.004 35.5 mon

Blood 2012 Aug 23rd.

Treatment for elderly patients

Not a candidate for transplant!

	MPT n = 129	MP n = 126	<i>P value</i>
CR	15.6%	3.7%	< 0.001
VGPR	29.3%	11.0%	< 0.001
PR	68.9%	47.6%	< 0.001
Median TTP	24.7 mo	15.0 mo	< 0.001
Median PFS	21.8 mo	14.5 mo	0.004
Median OS	45.0 mo	47.6 mo	0.79

Palumbo A, et al. *Blood*. 2008;112:3107-3114.

Treatment for elderly(2)

Combination	Response rate (%)	CR rate (%)
Bortezomib +Mel +Pred	70	30
Len +Mel+Pred	81	23.8
Mel + Pred + Thal	76	28



Lancet 2006;367:825-31, NEJM 2008;359:906-17,JCO 2007;25:4459-65

Thal-dexa vs Len-dexa: a phase 3 study

	CR + VGPR (%)	PR(%)	NR/Prog. dis
Thal/dexa (n=34)	32.4	38.2	29.3
Len/dexa (n=35)	37.2	40.0	22.8

Mukherjee et al, ASH,2011

Thal-dexa vs Len-dexa: a phase 3 study



Mukherjee et al. ASH2011

Induction therapy : Summary

- **No of drugs : 2 vs 3 vs 4 drugs**
 - Response rates higher with more drugs
 - Higher PFS
 - Overall survival : ? Generally not different
 - Toxicity : higher with more drugs
- **Suggestion**
 - Risk based approach
 - Patients Preference

Myeloma : Cytogenetics

Risk Group	Cytogenetics	Median OS
Poor (25%)	t (4;14) t (14;16) -17p13	24.7 months
Intermediate(17%)	-13q14	42.3 months
Good (58%)	All others	50.5 months

Hyperdiploidy - Good, hypodiploidy - poor risk


Fonesca et al. Blood 2003;101:4569-75

Risk score model for multiple myeloma: prediction of outcome


R i s k category (del13q14+ ISS)	n (%)	OS	<i>P</i> value	EFS	<i>P</i>	Response (CR+VGPR +PR)	<i>P</i> value
Low Risk (score ≥1)	41 (58%)	79%	0.004	55%	0.002	39	0.001
High Risk (score >1.0)	30 (42%)	53%		29%		19	

Sensitivity: 73.5%; Specificity: 75%; Positive predictive value: 90%


CR : Predictor of Survival (n=170)



CR : Predictor of Survival (n=170)



Treatment Approach




Summary : Treatment approach

Cure	Control
Maximize Response Multidrug induction	VGPR/nCR/CR Regimens to keep disease under control
ASCT : Single/Double Morbidity/mortality	ASCT at relapse
Allogeneic Stem cell Tx Morbidity/mortality	-
Impaired QOL	QOL : maintained

Impact of High-Risk Cytogenetic Risk Status on Outcome


	High Risk	Standard Risk
> PR	81%	89%
CR + VGPR	38%	45%
PFS (mo)	18.5	37
TTP (mo)	18.5	36.5
OS	92%	92%




Kapoor MD, et al. *Blood*. 2008;112(11). Abstract 95.

Outcomes for VMP Patients by Cytogenetic Risk*

Event Free Survival




Overall Survival






*Cytogenetics by FISH. High-risk: t(4;14), t(14;16), del(17p).


San Miguel JF, et al. *Blood*. 2008;112(11). Abstract 650.
Dimopoulos, et al. *Blood*. 2008;112. Abstract 1727.



Pre-treatment



Post Rx
Post treatment



Newer Agents in Clinical Trials

- **Proteasome inhibitors**
 - Carfilzomib
- **Immunomodulators**
 - Pomalidomide
- **HDAC inhibitors**
 - Vorinostat with bortezomib
- **Monoclonal antibodies**
 - CNTO 328 (α-IL6) with bortezomib
- **AKT inhibitor**
 - Perifosine with bortezomib and dex


Free light chain (FLC) assay

	Normal values
Serum free kappa levels	3.3 to 19.4 mg/dl
Serum free lambda levels	5.7 to 26.3 mg/dl
k/ λ ratio	0.26 to 1.65
k/ λ Ratio <0.26	Free Lambda chain
Ratio of 1.65	Free kappa chain

Survival

Overall Survival

AIIMS Experience



Progression - free Survival

